Swiss National Bank grew its holdings in shares of Invitae Co. (NYSE:NVTA) by 23.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 63,200 shares of the medical research company’s stock after purchasing an additional 11,800 shares during the period. Swiss National Bank owned approximately 0.12% of Invitae worth $574,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in NVTA. Teacher Retirement System of Texas bought a new stake in Invitae in the 4th quarter worth approximately $116,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Invitae during the 3rd quarter valued at $133,000. Voya Investment Management LLC lifted its stake in shares of Invitae by 51.2% during the 2nd quarter. Voya Investment Management LLC now owns 16,936 shares of the medical research company’s stock valued at $162,000 after buying an additional 5,733 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in shares of Invitae during the 3rd quarter valued at $180,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Invitae by 34.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,129 shares of the medical research company’s stock valued at $307,000 after buying an additional 8,244 shares in the last quarter. Institutional investors own 70.83% of the company’s stock.
Shares of NYSE:NVTA traded down $0.24 during midday trading on Friday, reaching $4.98. The company’s stock had a trading volume of 1,796,612 shares, compared to its average volume of 1,182,512. The firm has a market capitalization of $263.67, a P/E ratio of -1.88 and a beta of 1.06. Invitae Co. has a twelve month low of $4.35 and a twelve month high of $10.41. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.60 and a quick ratio of 2.60.
Invitae (NYSE:NVTA) last released its quarterly earnings data on Monday, February 12th. The medical research company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.17). The business had revenue of $25.40 million during the quarter, compared to analyst estimates of $24.18 million. Invitae had a negative return on equity of 124.43% and a negative net margin of 180.85%. The firm’s revenue was up 175.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.69) EPS. equities analysts anticipate that Invitae Co. will post -2.23 EPS for the current fiscal year.
NVTA has been the topic of several research analyst reports. Zacks Investment Research cut shares of Invitae from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th. Ladenburg Thalmann began coverage on shares of Invitae in a research note on Friday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Leerink Swann dropped their price objective on shares of Invitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 16th. Benchmark decreased their target price on shares of Invitae from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 16th. Finally, ValuEngine cut shares of Invitae from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $11.00.
In related news, insider Randal W. Scott bought 44,444 shares of the company’s stock in a transaction dated Monday, April 2nd. The shares were acquired at an average price of $4.50 per share, for a total transaction of $199,998.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bros. Advisors Lp Baker bought 1,111,111 shares of the company’s stock in a transaction dated Wednesday, March 28th. The stock was bought at an average price of $4.50 per share, for a total transaction of $4,999,999.50. The disclosure for this purchase can be found here. 9.90% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/swiss-national-bank-purchases-11800-shares-of-invitae-corp-nvta.html.
Invitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.